- Home
- RSLS vs ENSC Comparison
RSLS vs ENSC Comparison
Compare RSLS & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSLS
- ENSC
- Stock Information
- Founded
- RSLS 2002
- ENSC 2003
- Country
- RSLS United States
- ENSC United States
- Employees
- RSLS N/A
- ENSC N/A
- Industry
- RSLS Medical/Dental Instruments
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- RSLS Health Care
- ENSC Health Care
- Exchange
- RSLS Nasdaq
- ENSC Nasdaq
- Market Cap
- RSLS 3.2M
- ENSC 2.9M
- IPO Year
- RSLS 2007
- ENSC N/A
- Fundamental
- Price
- RSLS $0.31
- ENSC $1.76
- Analyst Decision
- RSLS Hold
- ENSC
- Analyst Count
- RSLS 1
- ENSC 0
- Target Price
- RSLS N/A
- ENSC N/A
- AVG Volume (30 Days)
- RSLS 36.0M
- ENSC 178.9K
- Earning Date
- RSLS 04-04-2025
- ENSC 05-12-2025
- Dividend Yield
- RSLS N/A
- ENSC N/A
- EPS Growth
- RSLS N/A
- ENSC N/A
- EPS
- RSLS N/A
- ENSC N/A
- Revenue
- RSLS $8,006,000.00
- ENSC $5,210,031.00
- Revenue This Year
- RSLS $52.80
- ENSC N/A
- Revenue Next Year
- RSLS N/A
- ENSC N/A
- P/E Ratio
- RSLS N/A
- ENSC N/A
- Revenue Growth
- RSLS N/A
- ENSC 133.58
- 52 Week Low
- RSLS $0.30
- ENSC $1.70
- 52 Week High
- RSLS $29.00
- ENSC $14.67
- Technical
- Relative Strength Index (RSI)
- RSLS 40.15
- ENSC 26.05
- Support Level
- RSLS $0.30
- ENSC $1.70
- Resistance Level
- RSLS $0.70
- ENSC $2.39
- Average True Range (ATR)
- RSLS 0.28
- ENSC 0.33
- MACD
- RSLS 0.04
- ENSC 0.05
- Stochastic Oscillator
- RSLS 0.36
- ENSC 4.18
About RSLS ReShape Lifesciences Inc.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.